Dashboard
Stock is technically in a Bearish range
- The technical trend has deteriorated from Mildly Bearish on 01-Sep-26 and has generated -52.53% returns since then
- Multiple factors for the stock are Bearish like MACD, Bollinger Band and KST
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
INR 155 Cr (Micro Cap)
11.00
40
0.00%
0.33
16.97%
1.95
Total Returns (Price + Dividend) 
Medico Remedies for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Medico Remedies Ltd is Rated Sell
Medico Remedies Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 15 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 November 2026, providing investors with the latest insights into the company’s performance and outlook.
Read More
Medico Remedies Ltd Falls to 52-Week Low of Rs 18.22 Amidst Prolonged Downtrend
A sustained decline has pushed Medico Remedies Ltd to a fresh 52-week low of Rs 18.22 on 6 Nov 2026, marking a 63.17% drop over the past year despite the broader market showing resilience.
Read More
Medico Remedies Ltd Falls to 52-Week Low of Rs 19 as Sell-Off Deepens
For the fifth consecutive session, Medico Remedies Ltd closed lower, breaching its 52-week low at Rs 19 on 28 Oct 2026, marking a 6.4% decline intraday despite opening with a modest gain. This persistent downward pressure has dragged the stock down by over 61% in the past year, significantly underperforming the broader Sensex, which itself is nearing its own 52-week low.
Read More Announcements 
Financial Results For Quarter Ended 30Th September 2026.
09-Nov-2026 | Source : BSEUnaudited Standalone Financial Results for Quarter ended 30th September 2026 along with Auditors limited review report.
Board Meeting Outcome for Intimation Under Regulation 30 (Read With Part A Of Schedule III) (Listing Obligations And Disclosure Requirements) Regulations 2015 ("Listing Regulations)
09-Nov-2026 | Source : BSE1.Unaudited Standalone Financial Results for the quarter ended 30th September 2026 alongwith Auditors
Board Meeting Intimation for Quarterly Financial Results
03-Nov-2026 | Source : BSEMedico Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2026 inter alia to consider and approve To consider and approve Unaudited Financial Results for the quarter ended 30th September2026 along with the Limited Review Report thereon.
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
Medico Remedies Ltd has announced 2:10 stock split, ex-date: 16 Mar 23
Medico Remedies Ltd has announced 3:1 bonus issue, ex-date: 16 Nov 21
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 2 Schemes (0.0%)
Held by 2 FIIs (0.6%)
Haresh Kapurlal Mehta (20.22%)
None
24.77%
Quarterly Results Snapshot (Standalone) - Sep'26 - YoY
YoY Growth in quarter ended Sep 2026 is 40.52% vs 33.77% in Sep 2025
YoY Growth in quarter ended Sep 2026 is -7.39% vs 65.81% in Sep 2025
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 29.57% vs -4.98% in Sep 2024
Growth in half year ended Sep 2025 is 40.26% vs -16.53% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 36.42% vs 5.83% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 26.26% vs 10.58% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'26
YoY Growth in year ended Mar 2026 is 36.73% vs 4.15% in Mar 2025
YoY Growth in year ended Mar 2026 is 30.03% vs 21.71% in Mar 2025